Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study

Autor: Gold, Ralf, Piani-Meier, Daniela, Kappos, Ludwig, Bar-Or, Amit, Vermersch, Patrick, Giovannoni, Gavin, Fox, Robert J, Arnold, Douglas L, Benedict, Ralph H B, Penner, Iris-Katharina, Rouyrre, Nicolas, Kilaru, Ajay, Karlsson, Göril, Ritter, Shannon, Dahlke, Frank, Hach, Thomas, Cree, Bruce A C

Publikováno v: Gold, Ralf; Piani-Meier, Daniela; Kappos, Ludwig; Bar-Or, Amit; Vermersch, Patrick; Giovannoni, Gavin; Fox, Robert J; Arnold, Douglas L; Benedict, Ralph H B; Penner, Iris-Katharina; Rouyrre, Nicolas; Kilaru, Ajay; Karlsson, Göril; Ritter, Shannon; Dahlke, Frank; Hach, Thomas; Cree, Bruce A C (2022). Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. Journal of neurology, 269(9), pp. 5093-5104. Springer 10.1007/s00415-022-11166-z
Journal of neurology, vol 269, iss 9

Background Siponimod is a sphingosine 1-phosphate receptor modulator approved for active secondary progressive multiple sclerosis (aSPMS) in most countries; however, phase 3 EXPAND study data are from an SPMS population with/without disease activity.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3a3ede73c18ab536dd9a61f4ed659de
https://doi.org/10.1007/s00415-022-11166-z

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

sj-docx-5-msj-10.1177_13524585221083194 – Supplemental material for Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years

Autor: Cree, Bruce AC, Arnold, Douglas L, Fox, Robert J, Gold, Ralf, Vermersch, Patrick, Benedict, Ralph HB, Bar-Or, Amit, Piani-Meier, Daniela, Rouyrre, Nicolas, Ritter, Shannon, Kilaru, Ajay, Karlsson, Goeril, Giovannoni, Gavin, Kappos, Ludwig

Supplemental material, sj-docx-5-msj-10.1177_13524585221083194 for Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years by Bruce AC Cree, Dougl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5118fc03968674f89ad300f70636686f

sj-docx-6-msj-10.1177_13524585221083194 – Supplemental material for Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years

Autor: Cree, Bruce AC, Arnold, Douglas L, Fox, Robert J, Gold, Ralf, Vermersch, Patrick, Benedict, Ralph HB, Bar-Or, Amit, Piani-Meier, Daniela, Rouyrre, Nicolas, Ritter, Shannon, Kilaru, Ajay, Karlsson, Goeril, Giovannoni, Gavin, Kappos, Ludwig

Supplemental material, sj-docx-6-msj-10.1177_13524585221083194 for Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years by Bruce AC Cree, Dougl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a141380849ad98c558821ecd66ff0635

sj-docx-8-msj-10.1177_13524585221083194 – Supplemental material for Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years

Autor: Cree, Bruce AC, Arnold, Douglas L, Fox, Robert J, Gold, Ralf, Vermersch, Patrick, Benedict, Ralph HB, Bar-Or, Amit, Piani-Meier, Daniela, Rouyrre, Nicolas, Ritter, Shannon, Kilaru, Ajay, Karlsson, Goeril, Giovannoni, Gavin, Kappos, Ludwig

Supplemental material, sj-docx-8-msj-10.1177_13524585221083194 for Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years by Bruce AC Cree, Dougl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::941747df72001506c286c40d3e7177cb